Skip to main content

O'Neill Vincent's Form 4 filing

BioXcel Therapeutics, Inc. (BTAIQ) · filed Mar 16, 2023

Accession no.
0001104659-23-033402
Filed
Mar 16, 2023
Trade date
Mar 14-15, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 3 derivative transactions. Open-market sales total $16.6K. It was filed 2 days after the trade.

This filing was later replaced by the amendment 0001104659-24-072998 (Jun 18, 2024). Trade tables on this site use the amended version.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
O'Neill VincentCIK 0001672718Officer (Chief Medical Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 14, 2023Common StockMOption exerciseAcquired+2,084––2,084Direct
Mar 15, 2023Common StockSSaleDisposed−845$19.70−$16,646.51,239Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 14, 2023Common StockMOption exerciseDisposed−2,084$0.00$06,253Direct
Mar 15, 2023Common StockAGrant or awardAcquired+9,000$0.00$09,000Direct
Mar 15, 2023Common StockAGrant or awardAcquired+32,000$0.00$032,000Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)